| 主权项 |
1. A compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt or solvate thereof, wherein A is a moiety of formula II linked through its terminal —NH group to any carbon atom of the pyridine, ring: R1 is absent or 1 to 54 substituents each independently selected from the group consisting of halogen, —CN, —OH, —NO2, —N(R6)2, —OCF3, —CF3, —OR6, —COR6, —COOR6, —CON(R6)2, —OCOOR6, —OCON(R6)2, —(C1-C8)alkylene-COOR6, —SR6, —SO2R6, —SO2N(R6)2, and —S(═O)R6, wherein said —(C1-C8)alkyl and —(C1-C8)alkylene-COOR6 may optionally be substituted with —OH, —OR3, —OCF3, —CF3, —COR3, —COOR3, —OCOOR3, —OCON(R3)2, —(C1-C8)alkylene-COOR3, —CN, —NH2, —NO2, —SH, —SR3, —(C1-C8)alkyl, —N(R3)2, —CON(R3)2, —SO2R3, or —S(═O)R3, or two adjacent R1 groups and the carbon atoms to which they are attached form a 5- or 6-membered carbocyclic or heterocyclic ring, (C6-C10)aryl, or 6- to 10-membered heteroaryl; R2 each independently is selected from the group consisting of H, halogen, —OCF3, —CF3, —OR7, —COR7, —COOR7, —OCOOR7, —OCON(R7)2, —(C1-C8)alkylene-COOR7, —CN, —NO2, —SH, —SR7, —N(R7)2, —CON(R7)2, —SO2R7, SO2N(R7)2, and —S(═O)R7; R3 each independently is selected from the group consisting of (C1-C8)alkyl, (C2-C8)alkenyl, and (C2-C8)alkynyl; R4 is selected from the group consisting of H, —COOR7, —(C1-C8)alkylene-COOR7, —CN, —(C1-C8)alkyl, and —CON(R7)2; R5 is selected from the group consisting of H, —OH, —CO—(C1-C8)alkyl, —COO—(C1-C8)alkyl, —CN, and —NH2; R6 each independently is selected from the group consisting of H, (C1-C8)alkyl, (C3-C10)cycloalkyl, 4-12-membered heterocyclyl, (C6-C14)aryl, and —(C1-C8)alkylene-NH2; and R7 each independently is selected from the group consisting of H, (C1-C8)alkyl, — (C1-C8)alkylene-NH2, (C3-C10)cycloalkyl, 4-12-membered heterocyclyl, and (C6-C14)aryl, each of which other than H may optionally be substituted with —OR6, —COR6, —COOR6, —OCOOR6, —OCON(R6)2, —(C1-C8)alkylene-COOR6, —CN, —NO2, —SR6, —N(R6)2, —CON(R6)2, —SO2R6, or —S(═O)R6. |
